Neoadjuvant docetaxel-based chemotherapy followed by en bloc resection is an effective treatment for locally advanced esophageal adenocarcinoma. Results from a 15-year retrospective analysis showed that both docetaxel/cisplatin/5FU and 5FU/leucovorin/oxaliplatin/docetaxel regimens achieved similar survival outcomes. A high percentage of patients completed the neoadjuvant cycles, and the majority achieved an R0 resection. Although the median lymph node yield was 32 and 60.6% of patients had positive lymph nodes, overall survival was comparable between the treatment groups.
Journal Article by Tankel J, Ahmed N (…) Ferri L et 16 al. in Ann Surg Oncol
© 2023. Society of Surgical Oncology.